Idorsia

team layoffs workforce
Biotech

Idorsia's Tryvio sale behind schedule, but layoffs on track

Idorsia’s plans to sell its hypertension drug Tryvio have faced a speed bump, even as the biotech plows ahead with around 250 layoffs.
James Waldron Dec 20, 2024 4:42am
A series of dice with a bag on them illustrating cost cuts

Idorsia teases Tryvio licensing deal while planning 270 layoffs

Nov 27, 2024 4:15am
cancel

Neurocrine, Idorsia part ways 2 years after double phase 2 fails

Oct 29, 2024 7:15am
timer sand clocks time

Idorsia bags $350M upfront from Viatris for 2 late-phase assets

Feb 28, 2024 7:56am
Graphic of employees walking out depicting layoffs

Idorsia lays off 300 staff after previewing cost cuts in July

Oct 24, 2023 10:30am
Idorsia

J&J hands back $230M blood pressure drug with approval in sight

Sep 6, 2023 6:20am